Earnings ·
Clene reports Q3 net income of $3.9M and submits NDA for CNM-Au8 in ALS
CLNNClene Inc.
Clene Inc. reported a third-quarter 2026 net income of $3.9 million, or $0.30 per basic share, compared to a net loss of $8.8 million in the prior-year period. The turnaround was driven by a $10.3 million gain from changes in the fair value of warrant and derivative liabilities, alongside operating expenses of $6.4 million. Cash and cash equivalents rose to $9.9 million as of September 30, 2026, providing an operating runway through mid-first quarter 2027. The company also announced it submitted a New Drug Application (NDA) to the FDA in October seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis (ALS). Clene is a late clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases.